Omeros ACL surgery drug fails in Phase III trials
OMS103HP did not meet the pre-specified endpoints of these studies. No conclusions were made regarding the drug-effect due to confounding factors in the studies. Omeros chairman and chief
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.